NEW ORLEANS — Described by its authors as “a one-stop shop” for the primary prevention of cardiovascular disease, a new guideline released March 17 by the American Heart Association (AHA) and the American College of Cardiology (ACC) runs the gamut from smoking cessation strategies to specific recommendations for treating cholesterol based on a patient’s 10-year risk of atherosclerotic cardiovascular disease.
The FDA’s preliminary investigation into the long-term safety of paclitaxel-coated balloons and stents revealed those devices are associated with a 50 percent higher risk of death than control devices used to treat femoropopliteal artery disease.
Air pollution could be contributing to twice as many deaths as previously estimated, according to research published in the European Heart Journal. Cardiovascular disease often deals the final blow, with CVD events accounting for 40 to 80 percent of these deaths.
The Early Bird Bleed Monitoring System, which can detect internal bleeding during endovascular procedures, has been granted de novo classification by the FDA. The approval was announced March 5 by Saranas, the device’s manufacturer.
Despite living in a country with universal healthcare, Canadians residing in rural areas have more vascular risk factors and a higher incidence of stroke, even after adjusting for comorbidities and sociodemographic conditions.
Employees at Baylor St. Luke’s Medical Center in Houston made 122 mistakes in the labeling of blood over a four-month period, according to a federal review prompted by the December death of a 75-year-old woman who received the wrong blood type and died after suffering repeated bouts of cardiac arrest.
When endovascular thrombectomy procedures for acute ischemic stroke take more than an hour or require more than three attempts to remove the clot, outcomes significantly worsen, according to a study published Feb. 25 in the Journal of the American College of Cardiology.
The FDA issued a safety alert Feb. 25 warning that a 10 mg, twice-daily dose of tofacitinib—sold under the brand names Xeljanz and Xeljanz XR—has been linked to an increased risk of pulmonary embolism and death in patients with rheumatoid arthritis. That dose is only approved for patients with ulcerative colitis, the agency said.
A national cardiovascular disease screening project in China revealed fewer than 3 percent of high-risk participants were taking either statins or aspirin—a finding researchers described as a “wake-up call” for middle- and low-income countries which are struggling to combat their worsening CVD risk profiles.
In the latest twist in the debate over the long-term safety of paclitaxel-coated balloons and stents, a correction published Feb. 19 in Circulation said the five-year mortality results of the Zilver PTX randomized trial were “inadvertently reversed”—and that uncoated devices were actually associated with better survival.
A startup that sold young donors’ blood to consumers in several states with the goal of treating conditions such as dementia, Alzheimer’s disease and heart disease has apparently shut down in the wake of an FDA statement that the blood-infusion technique has no scientific merit.